THE first and thus far only reversal agent for a non vitamin K antagonist oral anticoagulant (NOAC) has been given a boost with the release of results from a large patient study presented at the American Heart Association (AHA) Scientific Sessions 2016 in New Orleans, Louisiana.
Idarucizumab, marketed in Australia as Praxbind by Boehringer Ingelheim, was successfully trialled in a study involving 494 patients requiring reversal of their dabigatran (Pradaxa) anticoagulation for a variety of reasons.
The primary endpoint of reversal of the anticoagulant effect of dabigatran within four hours was 100% as measured by diluted thrombin time and ecarin clotting time.
CLICK HERE for more detail.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Nov 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Nov 16
